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Summary Introduction
The fragile X syndrome is an X-linked mental retardation The identiﬁcation of genes and their mutations has facili-
disorder caused by an expanded CGG repeat in the ﬁrst tated direct molecular diagnosis of numerous genetic
exon of the fragile X mental retardation (FMR1) gene. Its disorders (McKusick 1995). The criteria for introduc-
frequency, X-linked inheritance, and consequences for rela- tion of new diagnostic procedures, such as target groups
tives all prompt for diagnosis of this disorder on a large and an active or passive approach, are still under debate
scale in all affected individuals. A screening for the fragile for several genetic disorders, including the fragile X syn-
X syndrome has been conducted in a representative sample drome (Bonthron and Strain 1993; Bundey and Norman
of 3,352 individuals in schools and institutes for the men- 1993; Howard-Peebles et al. 1993; Palomaki and Had-
tally retarded in the southwestern Netherlands, by use of a dow 1993; American College of Medical Genetics 1994;
brief physical examination and the DNA test. The attitudes Craft 1995; Laxova 1995). The fragile X syndrome
and reactions of (non)consenting parents/guardians were screening program presented here gives a model for ac-
studied by (pre- and posttest) questionnaires. A total of tively introducing a newDNA diagnostic procedure and,
2,189 individuals (65%) were eligible for testing, since they moreover, a method to obtain accurate prevalence data.
had no valid diagnosis, cerebral palsy, or a previous test for The fragile X syndrome is characterized by X-linked
the FMR1 gene mutation. Seventy percent (1,531/2,189)
mental retardation with additional features such as a
of the parents/guardians consented to testing. Besides 32
long face with large protruding ears, macroorchidism,
previously diagnosed fragile X patients, 11 new patients (9
and eye-gaze avoidance (Fryns 1989; Hagerman 1996).males and 2 females) were diagnosed. Scoring of physical
Affected males and most of the affected females show afeatures was effective in preselection, especially for males
fragile site at Xq27.3 in a percentage of the cells tested(sensitivity .91 and speciﬁcity .92).Majormotives to partici-
under special culture conditions (Sutherland and Hechtpate in the screening were the wish to obtain a diagnosis
1985); that method was used until the cloning of the(82%), the hereditary implications (80%), and the support
gene. The ﬁrst estimates of the prevalence of the fragileof research into mental retardation (81%). Thirty-four per-
X syndrome, based on cytogenetic testing, were 1/cent of the parents/guardians will seek additional diagnostic
1,000–1/2,600 for males and 1/2,000–1/4,000 for fe-workup after exclusion of the fragile X syndrome. The
males (Turner et al. 1986; Webb et al. 1986).prevalence of the fragile X syndrome was estimated at 1/
The cloning of the fragile X mental retardation6,045 for males (95% conﬁdence interval 1/9,981–1/
(FMR1) gene in 1991 (Oberle´ et al. 1991; Verkerk et3,851). On the basis of the actual number of diagnosed
al. 1991; Yu et al. 1991) enabled an accurate molecularcases in the Netherlands, it is estimated that ú50% of the
diagnosis. Affected individuals have expanded CGG re-fragile X cases are undiagnosed at present.
peats (ú200) in the ﬁrst exon of the FMR1 gene (the
so-called full mutation). This expansion is accompanied
by hypermethylation of the repeat and its upstream re-
gion, resulting in a shutdown of transcription and ab-
sence of the FMR1 protein (Pieretti et al. 1991; Sutcliffe
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a premutation will transmit this, usually unaltered, to Intellectual functioning—profound/severe (IQ õ30),
moderate (IQ 30–50), or mild mental retardation (IQtheir daughters.
Screening for the fragile X syndrome by DNA analysis 50–70)—was established by each individual’s psychol-
ogist, by IQ testing in schoolchildren, or by clinical esti-was offered to mentally handicapped individuals in
schools and institutes for the mentally retarded in the mation in the institutionalized individuals.
southwestern Netherlands. We analyzed the acceptance
DNA Analysisby parents/guardians of mentally retarded individuals,
A 10-ml blood sample was obtained from each indi-feasibility of such a screening program, and the preva-
vidual, and genomic DNA was isolated from blood leu-lence of the fragile X syndrome in the Dutch population.
kocytes (Miller et al. 1988). PCR analysis of the CGGThe pre- and posttest attitudes and expectations of con-
repeat was performed according to the method of Fu etsenting and nonconsenting relatives were studied.
al. (1991), with modiﬁcations (van den Ouweland et al.
1994). In all males without a fragment in the normalPatients and Methods
range (6–54 CGG repeats) and for all females without
Since 1992, a screening program for the fragile X two distinguishable normal fragments, additional
syndrome has been conducted in 5 institutions giving Southern blot analysis on HindIII-digested DNA, using
residential care (1,869 individuals aged 4–89 years, the intragenic probe pP2, was performed (Oostra et al.
mean age 39.0 years) and 16 special schools (1,483 indi- 1993).
viduals aged 5–21 years, mean age 13.0 years) for men-
Questionnaires to Consenting and Nonconsentingtally retarded individuals in the southwestern Nether-
Parents/Guardianslands. Persons without a known cause of their mental
handicap, without cerebral palsy (with quadriplegia), The acceptability of the screening program and the
and without previous DNA-mutation analysis of the (anticipated) implications of test results was assessed in
FMR1 gene (on the basis of medical records and previ- a pre- and posttest questionnaire study. A sample of
ous medical investigations) were eligible for a brief phys- consenting parents/guardians (nÅ 1,090) received a pre-
ical examination and venipuncture for DNA analysis of test questionnaire, after the blood sample was taken
the FMR1 gene. Parents/guardians were informed by from their relative, and a posttest questionnaire, 3 wk
letter and through information meetings. After the par- after the test result was obtained. A reminder was sent
ents/guardians’ written consent was obtained, the sub- after 3 wk. Nonconsenters (n Å 435) received a ques-
jects were included in the study. Organizations for par- tionnaire to ask them about their motives. A translation
ents/relatives were informed prior to the onset of the of the questionnaires is available on request.
program. Also, the medical, nursing, and teaching staff
Statistical Analysisof the various institutes and schools were informed in
separate meetings. Parents/guardians of newly diag- The data were analyzed with version 6.0 of SPSS for
nosed patients were offered genetic counseling and were Windows and the software Conﬁdence Interval Analysis
asked to participate in a follow-up study. The study (CIA) compiled by Gardner and Altman. The data are
was approved by the Medical Ethical Committee of the presented as a proportion or percentage with a 95%
Erasmus University and University Hospital Dijkzigt conﬁdence interval (CI). Differences between groups
(Rotterdam) and by the respective institutional ethical were assessed with the x2 test, and the signiﬁcance levels
review committees. (two tailed) will be presented.
Physical Examination Results
Each individual was scored by one of us for fragile X
Study Population, Physical Examination, andfeatures according to criteria of Laing et al. (1991) (fam-
DNA Testingily history of intellectual handicap, personality, large/
prominent ears, elongated face, and body habitus); addi- Sixty-ﬁve and one-half percent (2,170/3,313) of the
mentally retarded individuals were eligible for testing.tional items were hyperextensible ﬁnger joints, soft/
smooth skin, and macroorchidism. Additionally, the Reasons for exclusion of the other 1,143 individuals
included an earlier diagnosis of the fragile X syndromeheight and head circumference and dysmorphic features,
not related to the fragile X syndrome, were recorded. (32/1,143 [2.8%]); its exclusion by DNA testing (36/
1143 [3.1%]) or a causative diagnosis, such as DownBefore disclosure of the DNA test result, the individuals
were divided into low-, moderate-, and high-risk syndrome (474/1143 [41.5%]); or other valid diagno-
sis, including cerebral palsy, conﬁrmed by medical rec-groups—‘‘low’’ when dysmorphic features suggested a
diagnosis other than fragile X syndrome, ‘‘moderate’’ in ords (601/1,143 [52.6%]) (percentages of totals are
shown in table 1). Seventy percent (1,520/2,170) ofthe absence of speciﬁc dysmorphic features, and ‘‘high’’
in the presence of fragile X syndrome characteristics. the parents/guardians of eligible patients consented to
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Table 1
Overview of Study Sample: Gender and Level of Mental Retardation
NO. OF INDIVIDUALS
Moderate/Severe Mild
Males Females Males Females Total (% of Entire Sample)a
Not eligible for testing:
Fragile X syndrome 24 0 6 2 32 (1.0)
FMR1 mutation excluded 15 6 14 1 36 (1.1)
Down syndrome 230 204 20 20 474 (14.3)
Other chromosomal abnormality 18 29 2 6 55 (1.7)
Metabolic disorder 12 13 3 7 35 (1.1)
Cerebral palsy 133 100 8 6 247 (7.5)
Other 91 76 55 42 264 (8.0)
Subtotal 523 428 108 84 1,143 (34.5)
Eligible for testing:
Nonparticipants 213 194 161 82 650 (19.6)
Participants 533 461 333 193 1,520 (45.9)
Subtotal 746 655 494 275 2,170 (65.5)
Grand Total 1,269 1,083 602 359 3,313
a Excludes 39 patients with an unknown level of mental retardation.
participation. The use of the test was higher in the 5 male individuals studied (i.e., mild [IQ 50–70] andmod-
erate/severe retardation [IQ õ50]) (table 3). The estima-institutions than in the 16 special schools (74.4%
[95% CI 71.9%–76.9%] versus 64.6% [95% CI tion of the population prevalence is restricted to the data
from males in this study because females with a full61.6%–67.6%]). For 39 of the 3,352 individuals, the
level of intellectual development could not be ascer- mutation in the FMR1 gene have an intellectual develop-
ment varying from severely retarded to normal. The lat-tained, and those individuals were excluded in those
analyses for which this level was required. ter group was not included in this study among the
mentally retarded.A total of 1,501 of the 1,531 tested individuals (includ-
ing 11 with an unknown level of mental retardation who In the group of mildly retarded males (ntot Å 602), 4
fragile X patients (fp) were newly diagnosed among theare not included in table 1) had an CGG repeat in the
normal range (õ43 repeats). For 12% of the males and participants (np Å 333), for a relative prevalence (pp) of
.01201, and 6 fragile X patients (fne) had been previously59% of the females, the PCR test result was inconclusive,
and an additional Southern blot analysis was done. Al- diagnosed among the individuals who were not eligible
for testing (nne Å 108), for a relative prevalence (pne) ofthough no individuals with a premutation were detected,
19 individuals (1.2%) had an allele with a size in the .05555 (see table 3). If the relative prevalence in the
nonparticipating group (nnp Å 161) is assumed to be the‘‘intermediate range’’ (43–60 CGGs), and among those
was one female with an allele in the range of 55–60 CGG same as that in the participating group (namely, .01201),
repeats. Further study was feasible in the families of nine the total prevalence in the sample of mildly retarded
individuals (range 43–55 CGGs), and in those families
neither instability of the CGG repeat nor fragile X patients
could be detected. Eleven fragile X patients (0.7% [9 Table 2
males and 2 females]) were newly diagnosed. Seven of
Phenotype of Newly Diagnosed Fragile X Patientsthose resided in an institution, and four attended a special
school. Ten of 11 detected cases were in the group of 134
FREQUENCY OF
cases with a high risk for having the fragile X syndrome FRAGILE X
(on the basis of physical examination, sensitivity .91 [95% SYNDROME
PHENOTYPE SUGGESTIVECI .59–1.00], and speciﬁcity .92 [95% CI .90–.93].
OF FRAGILE X SYNDROME Males Females TOTALMoreover, all newly diagnosed male patients showed the
high-risk phenotype (table 2).
Low 0/223 0/251 0/474
Moderate 0/555 1/368 1/923Estimated Prevalence of the Fragile X Syndrome
High 9/92 1/42 10/134The prevalence of the fragile X syndrome was esti-
Total 9/870 2/661 11/1,531
mated for the various levels of mental retardation in
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Table 3
Prevalence of the Fragile X Syndrome, Estimated for Males in the Dutch Population
STUDY SAMPLE
Participants Nonparticipants Not eligible Total POPULATION
LEVEL OF
RETARDATION np fp pp nnp nne fne pne ntot ptot N F
Mild 333 4 .01201 161 108 6 .05555 602 .0198 30,000 595
Moderate/severe 533 5 .00938 213 523 24 .04589 1,269 .0244 27,000 660
866 9 374 631 30 1,871 57,000 1,255
males (ptot) is ([333/161]*.01201/ [108*.05555])/602 Motives for Participation or Nonparticipation
Å .0198. With an estimate of 30,000 mildly retarded Pretest attitude responses from consenting parents/
males (N) in the Netherlands (95% CI 27,700–33,300) guardians.—The response rate was 79% (860/1,090),
(Maas et al. 1988), one may expect 595 mildly retarded and most (71%) of the respondents were parents.
fragile X males (F) in this population (95% CI 309– Eighty-four percent had discussed the DNA test with
1,038). relatives and would inform them about the result. Major
In the sample of moderately/severely retarded males motives to participate were the wish to have a diagnosis,
(ntot Å 1,269), 5 fragile X patients (fp) were newly diag- the hereditary implications, and the support of research
nosed among the participants (np Å 533), for a relative into mental retardation (table 4). Eighteen percent of
prevalence (pp) of .00938, and 24 fragile X patients (fne) the respondents (95% CI 15%–21%) expected that the
had previously been diagnosed among the patients who fragile X syndrome would be diagnosed in their retarded
were not eligible for testing (nne Å 523), for a relative relative, 30% were uncertain (95% CI 27%–34%), and
prevalence (pne) of .04589. If the relative prevalence in 52% did not expect the diagnosis (95% CI 48%–55%).
the nonparticipating group (nnp Å 213) is assumed to Six percent had intrusive thoughts and/or feelings about
be the same as that in the participating group (namely, the test and its outcome (95% CI 5%–8%). Parents/
.00938), the total prevalence in the sample of moder- guardians of schoolchildren expected signiﬁcantly more
ately/severely retarded males (ptot) is ([533/213]*.00938 often that a diagnosis would improve the care of their
/ [523*.04589])/1,269 Å .0244. With an estimate of retarded family member than did parents/guardians of
27,000 moderately/severely retarded males (N) in the institutionalized individuals (table 4).
Netherlands (95% CI 23,700–29,500) (Maas et al. Posttest attitude responses from consenting parents/
1988), we estimated that the number of fragile X male guardians.—The response rate was 66% (681/1,030; a
patients with a moderate/severe mental handicap (F) follow-up questionnaire could not be sent to 51 parents/
should be 660 fragile X male patients (95% CI 451– guardians, and the parents/guardians of the newly diag-
932) in this population. nosed were offered genetic counseling). One-third
For the Netherlands, with 7,586,000 male residents (35%) of the respondents were relieved by the exclusion
(Statistical yearbook of the Netherlands 1995), a total of the fragile X syndrome (95% CI 31%–38%). One-
of 1,255 males with the fragile X syndrome will result third (95% CI 29%–37%) were not relieved, and 5%
in a prevalence of 1/6,045 for males (95% CI 1/9,981– (95% CI 3%–6%) were even disappointed. Eighteen
1/3,851). Varying the assumed relative prevalences in percent (95% CI 15%–21%) still worried about possi-
the nonparticipating group (half or double of the partici- ble genetic implications for their family. The majority
pating group) leads to prevalences for males that are (87%) had informed their relatives about the test result.
1/6,418 (95% CI 1/10,669–1/4,037) and 1/5,415 (95% After the exclusion of the fragile X syndrome in their
CI 1/8,719–1/3,538), respectively. relative, the parents/guardians of schoolchildren were
When a similar analysis is used for Down syndrome in signiﬁcantly more willing to pursue further investiga-
our male study sample (20 mildly and 230 moderately/ tions, both actively and passively, than were the parents/
severely retarded males with Down syndrome), a preva- guardians of institutionalized individuals (table 4). Re-
lence of 1/1,288 for Down syndrome males was found spondents (80% [95% CI 77%–83%]) appreciated the
(95% CI 1/1,538–1/1,087). This is similar to data from test and would recommend participation in such a pro-
the United Kingdom (Steele and Stratford 1995). The gram to others.
prevalence of the fragile X syndrome did not differ sig- Attitude responses from nonconsenting parents/guard-
niﬁcantly between the mildly retarded males and the ians.—The response rate was 35% (153/435). Noncon-
moderately/severely retarded males (.0198 and .0244, senters differed only by having signiﬁcantly higher edu-
cation levels than consenters (those having at least arespectively).
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Table 4
Motives for (Non)Participation, in Parents/Guardians of Mentally Retarded Individuals in Schools and Institutes
PERCENT OF INDIVIDUALS AGREEING (95% CI)a
Schools Institutes Total
Q Å 325 Q Å 535 Q Å 860 x2 P
Consenting parents/guardians:
Pretest
Wish to have a diagnosis 88 (85–92) 78 (75–82) 82 (79–85) 13.03 õ.001
Hereditary implications 79 (74–83) 81 (78–85) 80 (78–83) .33 .56
Support research into mental retardation 72 (67–77) 87 (85–90) 81 (79–84) 28.59 õõ.0001
Expecting better care after fragile X diagnosis 68 (63–73) 47 (43–52) 55 (52–59) 35.45 õ.0001
Q Å 248 Q Å 433 Q Å 681
Posttest
Will seek further investigations (‘‘active’’) 43 (37–50) 28 (24–32) 34 (30–37) 15.68 õ.0001
Will use new diagnostics when offered (‘‘passive’’) 78 (72–83) 57 (53–62) 65 (61–69) 28.87 õõ.0001
Q Å 55 Q Å 98 Q Å 153
Nonconsenting parents/guardians:
Blood test is too stressful for family member 42 (27–58) 73 (61–83) 61 (52–70) 13.68 õ.001
‘‘Deﬁnite’’ cause of mental handicap is known 27 (15–41) 54 (42–65) 44 (35–52) 10.59 õ.01
Any possible cause of retardation is different from
fragile X syndrome 56 (38–74) 69 (56–80) 64 (54–74) 2.08 .15
a Q Å number of questionnaires obtained.
high school–level education were 64% [95% CI 56%– ably lower than the previously reported prevalence of
1/1,000–1/2,600 (Turner et al. 1986; Webb et al. 1986)72%] and 47% [95%CI 43%–50%], respectively). The
majority (78%) had discussed the DNA test with others. but is similar to more-recent reports of 1/4,000–1/5,000
(England and Australia) (Murray et al. 1996; Turner etThe main reasons for nonconsenting were the opinion
that a deﬁnite cause of the mental handicap in their al. 1996). However, the sample sizes of these recent
studies did not allow very accurate estimates; nor wasrelative was already known or the conviction that any
possible cause must be different from the fragile X syn- a representative sampling of mentally retarded males
achieved. The earlier high estimates were obtained bydrome (table 4). Signiﬁcantly more often among non-
consenting parents of institutionalized persons, the test cytogenetic studies, with possible confounding either by
other fragile sites in this region of the X chromosomewas considered as too stressful for their relative (table
4). Nonparticipation was neither inﬂuenced by fear of or by false positives (Turner et al. 1996). The current
estimate might be conservative; the relative prevalence inpossible consequences of the test (9% [95% CI 4%–
6%]) nor by religion (6% [95% CI 2%–12%]). Gener- the nonparticipating group might be variously estimated
(see Results) but would minimally inﬂuence the estimate.ally, nonconsenters were not opposed to genetic testing
(72% [95% CI 64%–80%]). One-third (95% CI 24%– Also, the PCR method is not 100% sensitive, since frag-
ile X patients with mosaicism for a normal allele in42%) even considered the future use of other diagnostic
options if these would become available. combination with a full mutation might be missed.
However, these patients are very rare.
In the Netherlands, among 7.6 million males, 1,255Discussion
males with the fragile X syndrome may be expected,
probably without a difference between the distributionThis ﬁrst comprehensive genetic epidemiological
in mildly retarded males and that in moderately/se-study of a representative sample of male and female
verely retarded males. However, the seven clinical ge-mentally retarded individuals from a population (the
netic centers, covering the whole country, identiﬁedNetherlands) of 15 1 106 inhabitants, using DNA tech-
Ç450 male cases so far (B. A. Oostra, unpublishedniques for the fragile X syndrome, indicates that the
data). This suggests an underdiagnosis of ú50%. Inprevalence of the fragile X syndrome in males in the
general Dutch population is 1/6,045. This is consider- our study, one-fourth of the fragile X patients were
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newly diagnosed cases. This study included both insti- tion and informed their relatives, as was found else-
where (Turner et al. 1992).tutionalized (all ages) and noninstitutionalized (age
õ21 years) but no noninstitutionalized adult retarded The test procedure did not cause undue anxiety
among the participants, and most were interested in fu-individuals. Most people in the latter group work in
sheltered workshops and live either with their relatives ture diagnostic studies when these become available.
One-third of consenting parents/guardians arranged foror in sheltered homes. The fragile X syndrome is likely
to be most underdiagnosed in this group, because of the additional diagnostic investigations and genetic counsel-
ing, as was reﬂected by a sharp increase in referrals forlack of diagnostically oriented medical care for these
individuals. Improvement of genetic diagnosis in these clinical genetic and dysmorphological workup.
The observations in the nonconsenting group shouldsettings is important, also for counseling of the families.
Selection of male patients for FMR1 gene analysis be interpreted with caution, given the low response. Re-
luctance was felt because of ‘‘stressful’’ blood sampling.might be facilitated by evaluation of dysmorphic fea-
tures, since the presence of fragile X features was found That might be alleviated, in the future, by the FMR1
protein test, which requires only a few blood drops (Wil-to increase 10-fold the yield of positive molecular diag-
nosis (table 2). Such clinical preselection is less efﬁcient lemsen et al. 1995), or by a test using DNA isolated
from a mouthwash or cheek brush (Hagerman et al.for females, because of the variability of expression
of the full FMR1 mutation in females (Fryns 1989; 1994; Murray et al. 1996). The majority of the noncon-
senters believed that a ‘‘deﬁnite’’ cause for the handicapHagerman 1996).
Genetic carrier screening may be done at a young had already been established, however vague that diag-
nosis might have been. However, nonconsenters agreedadult age, especially to identify and inform female car-
riers of the pre- and full mutation prior to parenthood. with the general principle of performing DNA and other
diagnostic investigations among the mentally retarded.One study in the French Canadian population has sug-
gested a 1/259 frequency of premutation-carrier fe- Several goals of a diagnostic program—that is, estab-
lishment of a cause for mental retardation and moremales (Rousseau et al. 1995). Alternatively, screening
for the fragile X syndrome might start—as presented complete information and choice for parents and rela-
tives—are obviously achieved in this study. Even in ahere—among (young) mentally retarded individuals,
which will allow families of newly diagnosed cases the northwestern European country with well-developed di-
agnostic facilities,ú50% of fragile X cases seem undiag-option of avoiding the birth of a subsequent affected
child. However, genetic screening programs are under nosed at present. This reﬂects the slow rate of introduc-
tion of new diagnostic facilities in the care of thedebate, for reasons of privacy, the risk of medicaliza-
tion, the risk of losing insurance, and the lack of treat- mentally handicapped. In a period of DNA technology
and fears of genetic discrimination, this study shows thatment options. In the introduction of a screening pro-
gram among the mentally retarded, a careful parents/guardians of individuals with mental handicaps
have a realistic idea about potentials and limitations ofassessment of the acceptability by the families directly
involved is of primary importance. The present study new technologies, if they are adequately informed. The
fear of health-care authorities and others regarding ad-showed informed consent by parents or guardians in
71% of the eligible patients, which is in accordance verse effects of the study of larger groups of mentally
handicapped individuals may be alleviated by the realis-with other reports (Jacobs et al. 1993; Hagerman et
al. 1994; Slaney et al. 1995; Murray et al. 1996). tic appraisal seen on the part of those directly involved.
However, a high use of the test is only one of the
parameters of acceptance. Motives for consenting Appendix
were the wish to have a diagnosis, the possibility of
hereditary implications, and the support of research Other participants in the Rotterdam Collaborative frag-
ile X screening study group included M. de Groot, J.into mental retardation. In general, there was open-
ness in the family about having the relative tested: the van den Berg, P. Deman, J. van Grinsven, and H. Veere
(Craeyenburch, Nootdorp); A. Idzinga, A. Trappenburg,majority of consenting parents/guardians discussed
with others both the DNA test and its result. The W. Soeters, and C. Clement (HetWesterhonk,Monster);
E. Weijers and C. de Leeuw (SVVGR Rotterdam); L.pretest expectations of the consenting parents/guard-
ians seem realistically reserved, since only a minority Imschoot, J. den Hartigh, M. Heijkoop, and M. Dekker
(De Merwebolder, Sliedrecht); H. Hoogeveen, A. Vos-actually expected a diagnosis of the fragile X syn-
drome in their relative. However, none of the newly senaar, M. de Jager, and C. Ferero (GGD Rotterdam); S.
Mosterd (GGD Nieuwe Waterweg Noord); E. Gelsema-diagnosed cases had been anticipated by the parents/
guardians. Most parents of the newly diagnosed pa- Mudde, B. Becker, J. Akos, and T. de Jong (GGD Zuid-
Holland Zuid); L. van Elderen (GGD Zuid Hollandsetients felt relieved by the resolution of uncertainty and
by the lack of direct responsibility for the retardation. Eilanden); J. deWijs (GGD Stadsgewest Breda); H. Fran-
ken (GGD Streekgewest Westelijk Noord Brabant); J.They acknowledged the genetic nature of the condi-
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procedure for extracting DNA from nucleated cells. Nucleicde Ru (GGD Zeeland); M. Bommezijn (GGD Midden-
Acids Res 16:1215Holland); N. de Vries–van Waert (GGD Delftland); and
Murray A, Youings S, Dennis N, Latsky L, Linehan P,J. Wijnmaalen and L. Vorselen (Gorkum).
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